Simos Simeonidis, PhD
Managing Partner and Co-Founder @ Kos Biotechnology Partners
About
Dr. Simos Simeonidis is Managing Partner of Kos Biotechnology Partners, a global life sciences investment firm he co-founded in 2024 with Alex Tzoukas. He is also the Co-Founder and former CEO and Chairman of the Board of Directors of Delsona Therapeutics, a healthcare company spun out of Columbia University, that uses Focused Ultrasound to deliver therapeutics through the Blood Brain Barrier into the CNS, with applications in neurology (Alzheimer's, Parkinson's, ALS etc) and oncology (Glioblastoma Multiforme, DIPG etc).Dr. Simeonidis is a biotechnology industry expert with 30 years’ experience, who trained as an academic scientist, before transitioning to the biopharmaceutical industry and investment side of the sector. He spent a decade as a molecular geneticist dissecting signal transduction pathways and understanding mechanisms of disease (University of Chicago, Columbia, Harvard) and was appointed to the Faculty at Harvard Medical School and the Beth Israel Deaconess Medical Center. He transitioned out of academia, into the business side of industry, starting out with roles at Johnson & Johnson, GlaxoSmithKline and Novartis. Next, he spent more than a decade analyzing public and private biotechnology companies for a number of global investment banks (including Morgan Stanley, Cowen, RBC). He has also served as a board member in a number of private and public companies (Regulus Therapeutics, Sarissa Capital Acquisition Corporations, Shoreline Biosciences and Delsona Therapeutics). Prior to founding Kos Biotechnology Partners, Dr. Simeonidis held senior investment positions at Ally Bridge Group, a $2B global life sciences investment firm, where he was Managing Partner, co-CEO and co-CIO, and at Sarissa Capital Management, a $1.5B biotechnology-focused activist firm, where he was Partner, Senior Managing Director, Portfolio Manager and Co-Head of Investment Research. Dr. Simeonidis received his B.S. in Biology from Loyola University Chicago, and his M.A., M.Phil. and Ph.D. degrees in Cellular, Molecular and Biophysical Sciences from Columbia’s College of Physicians & Surgeons, where he cloned the mouse IkB epsilon gene. He completed his Postdoctoral Fellowship in the laboratory of Professor Tucker Collins at Harvard Medical School and the Brigham and Women’s Hospital, where he worked on the transcriptional regulation of gene expression via the NF-kB/IkB pathway. Dr. Simeonidis also holds an MBA in Healthcare Management from the Wharton School of the University of Pennsylvania.
-
United States
Financial Services
Portfolio Management, Alternative Investments, Investment Management, Risk Management, Hedge Funds, Healthcare, Biotechnology, Biopharmaceuticals, Investments, Risk Assessment, Financial Analysis, Mergers & Acquisitions (M&A), Research, Financial Modeling, Equity Research, Private Equity, Valuation, Equities, Financial Markets, Financial Statements
Experience
Managing Partner and Co-Founder
Kos Biotechnology Partners
New York, NY
Kos Biotechnology Partners is a global life sciences investment firm founded in 2024 by Simos Simeonidis and Alex Tzoukas. Dr. Simeonidis’s career started out in academia, as a molecular geneticist (Columbia and Harvard Medical Schools), before transitioning to the business and finance side of biopharma via an MBA in Healthcare Management at Wharton. This was followed by more than a decade as an analyst covering the biotechnology space for several investment banks (Morgan Stanley, Cowen, RBC), as a senior executive and board member in a number of healthcare companies (Novartis, Regulus, Sarissa Capital Acquisition Corporation, Shoreline, Delsona) and as a biotechnology investor at Sarissa Capital Management, Ally Bridge Group, before founding Kos Biotechnology Partners.
Co-Founder and Board Member
Delsona Therapeutics
New York, NY
2021-2023: Chairman of the Board of Directors 2023-2025: CEO and Chairman of the Board of Directors 2026-present: Member of the Board of Directorss Co-founder and Member of the Board of spin-out from Columbia University's Vagelos College of Physicians and Surgeons. We are developing a revolutionary approach to treating CNS diseases. Our focused ultrasound (FUS) technology has recently entered the clinic to treat patients with Alzheimer’s disease and pediatric brain cancer. Other areas of development include Parkinson’s disease, Huntington’s disease and Glioblastoma Multiforme.
Member Board of Directors
Fondation Sante
Fondation Santé was established by Dr. Stelios Papadopoulos and Dr. Spyros Artavanis-Tsakonas in 2000 as a private, non-profit foundation operating exclusively for charitable, scientific, and educational purposes. The goal of the foundation is to provide support for biomedical research in Greece.
co-CEO and co-CIO, Managing Partner
Ally Bridge Group
New York, New York, United States
co-CEO and co-CIO, Managing Partner of Ally Bridge Group (ABG) President and Portfolio Manager of Ally Bridge Group Public Equity Strategy Member of the Board of Directors at Ally Bridge MedAlpha International Fund Member of the Board of Directors at Shoreline Biosciences Led Ally Bridge Group (ABG), a global healthcare manager, with $2B AUM, focused on high-impact life science innovation across private and public markets, along with the firm's founder, as Managing Partner, co-CEO, co-CIO of the overall firm and President and Portfolio Manager of the firm’s public arm. Founded in 2013, ABG manages assets from offices in New York and Hong Kong, with the mission of generating superior risk-adjusted returns for investors by blending deep scientific and clinical research with financial and capital markets expertise.
Task Force for the Establishment of an Innovation-Based Biotechnology Industry in Greece
Government of the Hellenic Republic
New York, NY and Athens, Greece
Member of a Task Force of international biotechnology experts, assigned by the Prime Minister's Office, to perform a 2-year study on the feasibility and potential of the establishment of an innovation-based biotechnology industry in Greece. The Task Force was led by Dr. Stelios Papadopoulos, Chairman of the Board of Biogen, Exelixis, Regulus and Epikast, and included industry luminaries Albert Bourla, Noubar Afeyan, Spyros Artavanis-Tsakonas, Costis Maglaras, George Scangos, George Yancopoulos, Nick Galakatos, Emil Kakkis, Mene Pangalos, Eric Cantor and others. The Task Force completed the study and presented its findings to the Prime Minister and his team in May 2022.
Member Board Of Directors
Regulus Therapeutics
San Diego, California, United States
Institutional Investor in the company, Independent Director, Member of Nominating and Governance Committee
Partner, Co-Head of Research, Portfolio Manager and Senior Managing Director
Sarissa Capital Management LP
Greenwich, Connecticut, United States
Value investor in public and private biotech and pharma, using the tool of shareholder activism to generate returns. Sarissa Capital is a $1.5B fund, founded by former Carl Icahn healthcare portfolio manager Alex Denner, which invests in public and private biotech and pharma companies.
Managing Director, Senior Biotechnology Analyst
RBC Capital Markets
New York, NY
Senior analyst covering the biotechnology sector
Managing Director, Senior Biotechnology Analyst
Cowen Inc.
New York, NY
Senior analyst covering the biotechnology sector
Director, Senior Biotechnology Analyst
Rodman & Renshaw
New York, NY
Senior analyst covering the biotechnology sector
Education
The Wharton School
Healthcare Management
Harvard Medical School
Molecular Genetics
Investigated the role of the NF-kB/IkB on inflammation in vascular endothelium in the laboratory of Dr. Tucker Collins
Columbia University Vagelos College of Physicians and Surgeons
Cellular and Molecular Biology
Worked on cellular signal transduction via the NF-kB/IkB pathway. Cloned the third known inhibitor of NF-kB, IkB epsilon
Loyola University Chicago
Biological Sciences
Infectious disease research (Laboratory of Dr. Dominic Castignetti) NCAA Division I Varsity Soccer Most Improved Player of the Year Award (1991) Lakefront Hall Resident Assistant (1990-1992)
City Colleges of Chicago-Harold Washington College
English as a Second Language & Introductory College Courses
Varvakeio Model Lyceum
Simos Simeonidis, PhD's Contact Information
Phone
Find the Right Leads
Find Verified Contact Data
What LeadContact does well
Find verified emails, phone numbers, and decision-makers with 98% accuracy.
Find Leads
Find the right people by company, role, industry, location, and more.
925M+ professional profiles
Find Emails
Access verified email addresses for your target contacts.
657M+ emails
Find Phone Numbers
Get cross-validated phone data from multiple top sources.
239M+ phone numbers
More Accurate. Lower Cost.
Find contact data in 1 tool with 98% accuracy
LeadContact integrates leading enrichment tools to deliver more accurate contact data—without paying for each one.
Great conversations start with the right contact.
It’s time to find yours.